{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:09:27Z","timestamp":1761520167021,"version":"build-2065373602"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.clcc.2020.09.006","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T11:37:41Z","timestamp":1600429061000},"page":"e75-e81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1934-8408","authenticated-orcid":false,"given":"Atul","family":"Batra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Rigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malek B.","family":"Hannouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2020.09.006_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2020.09.006_bib4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2014.59.7633","article-title":"Metastatic colorectal cancer: current state and future directions","volume":"33","author":"Fakih","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clcc.2020.09.006_bib5","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.3747\/co.26.5575","article-title":"Metastatic colorectal cancer: therapeutic options for treating refractory disease","volume":"26","author":"Parmar","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1365-2036.2008.03684.x","article-title":"Review article: current management of metastatic colorectal cancer \u2013 the evolving impact of targeted drug therapies","volume":"27","author":"Yau","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clcc.2020.09.006_bib7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/EDBK_200929","article-title":"Molecular subtypes and the evolution of treatment decisions in metastatic colorectal cancer","volume":"38","author":"Dienstmann","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clcc.2020.09.006_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.2017-0203","article-title":"A\u00a0comprehensive review of sequencing and combination strategies of targeted agents in metastatic colorectal cancer","volume":"23","author":"Ciombor","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2020.09.006_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00384-018-3202-8","article-title":"Current status of immunotherapy in metastatic colorectal cancer","volume":"34","author":"Wrobel","year":"2019","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.clcc.2020.09.006_bib10","doi-asserted-by":"crossref","first-page":"9450754","DOI":"10.1155\/2018\/9450754","article-title":"Metastatic colorectal cancer in the era of personalized medicine: a more tailored approach to systemic therapy","volume":"2018","author":"Yu","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.clcc.2020.09.006_bib11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JGO.19.00367","article-title":"Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline","volume":"6","author":"Chiorean","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib12","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib13","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2020.09.006_bib14","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/annonc\/mdu055","article-title":"Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk","volume":"25","author":"Lestuzzi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib15","first-page":"E27","article-title":"Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease","volume":"93","author":"Tsibiribi","year":"2006","journal-title":"Bull Cancer"},{"key":"10.1016\/j.clcc.2020.09.006_bib16","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1200\/JCO.2009.27.3953","article-title":"Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle","volume":"28","author":"Jensen","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000072334","article-title":"High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients","volume":"65","author":"Wacker","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.clcc.2020.09.006_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clcc.2020.09.006_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187152506775268785","article-title":"Cardiotoxicity of 5-fluorouracil","volume":"4","author":"Alter","year":"2006","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.clcc.2020.09.006_bib20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/annonc\/mdh150","article-title":"5-Fluorouracil induces arterial vasocontractions","volume":"15","author":"S\u00fcdhoff","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib21","doi-asserted-by":"crossref","first-page":"7685","DOI":"10.1200\/JCO.2005.08.789","article-title":"Cardiotoxicity of cancer therapy","volume":"23","author":"Floyd","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib22","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/j.ijcard.2013.12.274","article-title":"Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge?","volume":"172","author":"Rateesh","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clcc.2020.09.006_bib23","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/sj.bjc.6600967","article-title":"Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity","volume":"88","author":"Cianci","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2020.09.006_bib24","doi-asserted-by":"crossref","first-page":"970","DOI":"10.21037\/jgo.2017.09.07","article-title":"Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm","volume":"8","author":"Clasen","year":"2017","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib25","first-page":"41","article-title":"Capecitabine-related cardiotoxicity: recognition and management","volume":"6","author":"Saif","year":"2008","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib26","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","volume":"10","author":"de Forni","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib27","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMra040958","article-title":"Systemic therapy for colorectal cancer","volume":"352","author":"Meyerhardt","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2020.09.006_bib28","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2020.09.006_bib29","first-page":"4363","article-title":"Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity","volume":"9","author":"van Kuilenburg","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2020.09.006_bib30","first-page":"181","article-title":"Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration","volume":"4","author":"Ezzeldin","year":"2004","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2020.09.006_bib31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2165\/00003495-199855030-00012","article-title":"A\u00a0review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer","volume":"55","author":"Gunasekara","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.clcc.2020.09.006_bib32","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2020.09.006_bib33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"first-page":"155","year":"2017","series-title":"Common Terminology Criteria for Adverse Events (CTCAE)","key":"10.1016\/j.clcc.2020.09.006_bib34"},{"key":"10.1016\/j.clcc.2020.09.006_bib35","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/annonc\/mdf091","article-title":"Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)","volume":"13","author":"Cascinu","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000084821","article-title":"First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer","volume":"68","author":"Aparicio","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.clcc.2020.09.006_bib37","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/sj.bjc.6602860","article-title":"Oncopaz Cooperative Group, Spain. Phase II randomised trial of raltitrexed\u2013oxaliplatin vs raltitrexed\u2013irinotecan as first-line treatment in advanced colorectal cancer","volume":"93","author":"Feliu","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2020.09.006_bib38","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/annonc\/mdf229","article-title":"Irinotecan and raltitrexed: an active combination in advanced colorectal cancer","volume":"13","author":"Carnaghi","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib39","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1245\/s10434-008-0015-y","article-title":"Is there a difference in survival between right- versus left-sided colon cancers?","volume":"15","author":"Meguid","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.14740\/gr1062w","article-title":"Difference between left-sided and right-sided colorectal cancer: a focused review of literature","volume":"11","author":"Baran","year":"2018","journal-title":"Gastroenterol Res"},{"key":"10.1016\/j.clcc.2020.09.006_bib41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s12885-019-5644-y","article-title":"Prognostic impact of tumor location in colon cancer: the Monitoring of Cancer Incidence in Japan (MCIJ) project","volume":"19","author":"Nakagawa-Senda","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2020.09.006_bib42","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/annonc\/mdm599","article-title":"Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy","volume":"19","author":"Soong","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ijc.10635","article-title":"Are there two sides to colorectal cancer?","volume":"101","author":"Iacopetta","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2020.09.006_bib44","first-page":"1757","article-title":"Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer","volume":"32","author":"Goto","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clcc.2020.09.006_bib45","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1089\/gtmb.2013.0171","article-title":"Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil","volume":"17","author":"Sulzyc-Bielicka","year":"2013","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.clcc.2020.09.006_bib46","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1158\/1078-0432.CCR-05-0141","article-title":"High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies","volume":"11","author":"Ricciardiello","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2020.09.006_bib47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/bjc.1998.423","article-title":"New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed (\u2018Tomudex\u2019)","volume":"77","author":"Blackledge","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2020.09.006_bib48","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0140-6736(02)08514-8","article-title":"British MRC Colorectal Cancer Working Party. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial","volume":"359","author":"Maughan","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2020.09.006_bib49","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.ejca.2008.07.002","article-title":"Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)","volume":"44","author":"Popov","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2020.09.006_bib50","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2407-2-2","article-title":"Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan\/5-fluorouracil\/leucovorin chemotherapy","volume":"2","author":"Tsavaris","year":"2002","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2020.09.006_bib51","first-page":"64","article-title":"Efficacy and cardiotoxic safety profile of raltitrexed in fluoropyrimidines-pretreated or high-risk cardiac patients with GI malignancies: large single-center experience","volume":"18","author":"Khan","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2020.09.006_bib52","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/A:1011178111295","article-title":"Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer","volume":"12","author":"Volk","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.09.006_bib53","first-page":"2910","article-title":"Pemetrexed monotherapy as salvage treatment in patients with metastatic colorectal cancer refractory to standard chemotherapy: a phase II single-arm prospective trial","volume":"9","author":"Lim","year":"2018","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.clcc.2020.09.006_bib54","first-page":"56","article-title":"Pemetrexed in advanced colorectal cancer","volume":"18","author":"Louvet","year":"2004","journal-title":"Oncology (Williston Park, NY)"},{"key":"10.1016\/j.clcc.2020.09.006_bib55","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3747\/co.19.891","article-title":"Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis","volume":"19","author":"Al-Saleh","year":"2012","journal-title":"Curr Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002820301353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002820301353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:07:13Z","timestamp":1761520033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002820301353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1533002820301353"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2020.09.006","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2020.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}